Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xenetic Biosciences's Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.39 Mil. Therefore, Xenetic Biosciences's EV-to-EBIT ratio for today is 0.42.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Xenetic Biosciences's Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.39 Mil. Therefore, Xenetic Biosciences's EV-to-EBITDA ratio for today is 0.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Xenetic Biosciences's Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $3.19 Mil. Therefore, Xenetic Biosciences's EV-to-Revenue ratio for today is -0.31.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Xenetic Biosciences (NAS:XBIO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Xenetic Biosciences's current Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.39 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Xenetic Biosciences's current Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.39 Mil.
Xenetic Biosciences's current Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.19 Mil.
Xenetic Biosciences's current Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82 Mil.
Xenetic Biosciences's current Enterprise Value is $-1.00 Mil.
Xenetic Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences Enterprise Value Related Terms
Xenetic Biosciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBIO vs ACXP, SILO, GOVX: Enterprise Value Comparison
For the Biotechnology subindustry, Xenetic Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Xenetic Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (XBIO) has a Enterprise Value of $-1.00 Mil as of Jul. 05, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Enterprise Value too high?
Xenetic Biosciences' current Enterprise Value is $-1.00 Mil. Overall, Xenetic Biosciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Enterprise Value compare to ACXP and SILO?
Xenetic Biosciences' Enterprise Value of $-1.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Enterprise Value is $-1.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.19, compared to a current price of $2.77 — trading 33.9% below its estimated fair value. The current Enterprise Value is $-1.00 Mil. Xenetic Biosciences' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Enterprise Value is $-1.00 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $2.77 is trading 33.9% below its estimated GF Value™ of $4.19.
GuruFocus considers Xenetic Biosciences to be Possible Value Trap.
Key valuation signals for XBIO:
Enterprise Value: $-1.00 Mil
GF Value™: $4.19 vs. price of $2.77 (33.9% below fair value)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
79GF Score
Get the complete analysis for XBIO
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
